Wendy Zadeh - Academia.edu (original) (raw)

Wendy Zadeh

Uploads

Papers by Wendy Zadeh

Research paper thumbnail of Safety and Effectiveness of Lacosamide as Adjunctive Treatment for Partial-onset Seizures (POS) in Hispanic/Latino Patients from Mexico: Post-hoc Analysis of an Open-label Trial (P4.265)

Neurology, 2015

OBJECTIVE: To explore the safety and effectiveness of lacosamide as first add-on (FAO) or later a... more OBJECTIVE: To explore the safety and effectiveness of lacosamide as first add-on (FAO) or later add-on (LAO) treatment of POS in Hispanic/Latino patients from Mexico. BACKGROUND: Lacosamide has demonstrated efficacy and safety as add-on therapy in patients receiving 1-3 concomitant AEDs. DESIGN/METHODS: This multinational open-label trial (NCT00955357) enrolled patients with uncontrolled seizures (≤40 POS/28 days, 蠅3 in total during the preceding 12 weeks). Lacosamide was initiated as FAO to initial monotherapy (epilepsy duration ≤24 months) or as LAO to 1-3 concomitant anti-epileptic drugs (AEDs; after 蠅2 previous AEDs; epilepsy duration 蠅5 years). Lacosamide was titrated over 6 weeks from 100mg/day to a 400mg/day target dose. The primary variable for this study was the proportion of patients who were seizure free for the first 12 weeks (MP1) of the 24-week Maintenance Phase (MP1+MP2). This post-hoc analysis consisted of Hispanic/Latino patients from Mexico. RESULTS: 102/456 (22.4[...

Research paper thumbnail of Evaluation in Diagnosis and Management of Diabetic Neuropathy

Journal of Diabetes Mellitus, 2021

The 100-year anniversary of insulin is explored by focusing on diabetic neuropathy. Neuropathy is... more The 100-year anniversary of insulin is explored by focusing on diabetic neuropathy. Neuropathy is so common to diabetes, it is well described even in the earliest accounts of diabetes. This article reviews the most common neuropathy syndromes, and the consensus of effective treatment for neuropathic pain. Pharmacological advances in neuropathy are still largely focused on pain control, not neuropathy intervention. The article reviews the established and lesser tested therapies used for pain control. It also reviews the pathophysiology of the disease state, including the many factors and steps that culminate to produce neuropathy and its different iterations. In the future, new ways to treat diabetic neuropathy may be geared toward treating specific pathophysiological step-points on the way to nerve damage. In the future, prevention and a deeper look at the impact of socioeconomic status as a predictor of diabetes will hopefully encompass a bigger part of pre-diabetic care.

Research paper thumbnail of Safety and Effectiveness of Lacosamide as a First Add-on (FAO) or Later Add-on (LAO) Treatment of Partial-onset Seizures (POS) in Adults: an Open-label Trial (P4.262)

Research paper thumbnail of Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: A multicentre open-label trial

Seizure, 2015

To evaluate the efficacy and safety of lacosamide administered as either first add-on or later ad... more To evaluate the efficacy and safety of lacosamide administered as either first add-on or later add-on antiepileptic drug (AED) therapy for patients with uncontrolled partial-onset seizures (POS). Methods: In this open-label, multicentre trial, patients with POS initiated oral lacosamide (titrated to 400 mg/day) either as add-on to first AED monotherapy, or as later add-on to 1-3 concomitant AEDs after !2 previous AEDs. The primary efficacy variable was the proportion of patients achieving seizure freedom for the first 12 weeks of the 24-week Maintenance Phase. Results: 456 patients received !1 dose of lacosamide (96 as first add-on, 360 as later add-on). In the first add-on cohort, 27/72 (37.5%) patients completed 12 weeks treatment and remained seizurefree; 18/68 (26.5%) remained seizure-free after 24 weeks. 64/91 (70.3%) patients achieved !50% reduction in seizure frequency during maintenance treatment. This was accompanied by a mean 7.1 AE 16.00 point improvement from Baseline in the Quality of Life Inventory in Epilepsy (QOLIE-31-P) total score for 24-week completers, with improvement reported in all subscales. Most common treatment-emergent adverse events (TEAEs) were dizziness (31.3%) and headache (13.5%). In the later add-on cohort, 39/261 (14.9%) and 29/249 (11.6%) patients remained seizure-free after completing 12 and 24 weeks' treatment, respectively. 178/353 (50.4%) patients achieved !50% reduction in seizure frequency during maintenance treatment. Mean change in QOLIE-31-P total score was 4.8 AE 14.74 points among 24-week completers. Common TEAEs were dizziness (33.6%), somnolence (15.0%) and headache (11.4%). Conclusions: Lacosamide initiated as first add-on treatment was efficacious and well tolerated in patients with uncontrolled POS.

Research paper thumbnail of Safety and Effectiveness of Lacosamide as Adjunctive Treatment for Partial-onset Seizures (POS) in Hispanic/Latino Patients from Mexico: Post-hoc Analysis of an Open-label Trial (P4.265)

Neurology, 2015

OBJECTIVE: To explore the safety and effectiveness of lacosamide as first add-on (FAO) or later a... more OBJECTIVE: To explore the safety and effectiveness of lacosamide as first add-on (FAO) or later add-on (LAO) treatment of POS in Hispanic/Latino patients from Mexico. BACKGROUND: Lacosamide has demonstrated efficacy and safety as add-on therapy in patients receiving 1-3 concomitant AEDs. DESIGN/METHODS: This multinational open-label trial (NCT00955357) enrolled patients with uncontrolled seizures (≤40 POS/28 days, 蠅3 in total during the preceding 12 weeks). Lacosamide was initiated as FAO to initial monotherapy (epilepsy duration ≤24 months) or as LAO to 1-3 concomitant anti-epileptic drugs (AEDs; after 蠅2 previous AEDs; epilepsy duration 蠅5 years). Lacosamide was titrated over 6 weeks from 100mg/day to a 400mg/day target dose. The primary variable for this study was the proportion of patients who were seizure free for the first 12 weeks (MP1) of the 24-week Maintenance Phase (MP1+MP2). This post-hoc analysis consisted of Hispanic/Latino patients from Mexico. RESULTS: 102/456 (22.4[...

Research paper thumbnail of Evaluation in Diagnosis and Management of Diabetic Neuropathy

Journal of Diabetes Mellitus, 2021

The 100-year anniversary of insulin is explored by focusing on diabetic neuropathy. Neuropathy is... more The 100-year anniversary of insulin is explored by focusing on diabetic neuropathy. Neuropathy is so common to diabetes, it is well described even in the earliest accounts of diabetes. This article reviews the most common neuropathy syndromes, and the consensus of effective treatment for neuropathic pain. Pharmacological advances in neuropathy are still largely focused on pain control, not neuropathy intervention. The article reviews the established and lesser tested therapies used for pain control. It also reviews the pathophysiology of the disease state, including the many factors and steps that culminate to produce neuropathy and its different iterations. In the future, new ways to treat diabetic neuropathy may be geared toward treating specific pathophysiological step-points on the way to nerve damage. In the future, prevention and a deeper look at the impact of socioeconomic status as a predictor of diabetes will hopefully encompass a bigger part of pre-diabetic care.

Research paper thumbnail of Safety and Effectiveness of Lacosamide as a First Add-on (FAO) or Later Add-on (LAO) Treatment of Partial-onset Seizures (POS) in Adults: an Open-label Trial (P4.262)

Research paper thumbnail of Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: A multicentre open-label trial

Seizure, 2015

To evaluate the efficacy and safety of lacosamide administered as either first add-on or later ad... more To evaluate the efficacy and safety of lacosamide administered as either first add-on or later add-on antiepileptic drug (AED) therapy for patients with uncontrolled partial-onset seizures (POS). Methods: In this open-label, multicentre trial, patients with POS initiated oral lacosamide (titrated to 400 mg/day) either as add-on to first AED monotherapy, or as later add-on to 1-3 concomitant AEDs after !2 previous AEDs. The primary efficacy variable was the proportion of patients achieving seizure freedom for the first 12 weeks of the 24-week Maintenance Phase. Results: 456 patients received !1 dose of lacosamide (96 as first add-on, 360 as later add-on). In the first add-on cohort, 27/72 (37.5%) patients completed 12 weeks treatment and remained seizurefree; 18/68 (26.5%) remained seizure-free after 24 weeks. 64/91 (70.3%) patients achieved !50% reduction in seizure frequency during maintenance treatment. This was accompanied by a mean 7.1 AE 16.00 point improvement from Baseline in the Quality of Life Inventory in Epilepsy (QOLIE-31-P) total score for 24-week completers, with improvement reported in all subscales. Most common treatment-emergent adverse events (TEAEs) were dizziness (31.3%) and headache (13.5%). In the later add-on cohort, 39/261 (14.9%) and 29/249 (11.6%) patients remained seizure-free after completing 12 and 24 weeks' treatment, respectively. 178/353 (50.4%) patients achieved !50% reduction in seizure frequency during maintenance treatment. Mean change in QOLIE-31-P total score was 4.8 AE 14.74 points among 24-week completers. Common TEAEs were dizziness (33.6%), somnolence (15.0%) and headache (11.4%). Conclusions: Lacosamide initiated as first add-on treatment was efficacious and well tolerated in patients with uncontrolled POS.

Log In